279 related articles for article (PubMed ID: 34044735)
1. Hydroxychloroquine in obstetric antiphospholipid syndrome: rationale and results of an observational study of refractory cases.
Khizroeva J; Bitsadze V; Tincani A; Makatsariya A; Arslanbekova M; Babaeva N; Tsibizova V; Shkoda A; Makatsariya N; Tretyakova M; Solopova A; Gadaeva Z; Vorobev A; Khamani I; Aslanova Z; Nakaidze I; Mischenko A; Grigoreva K; Kunesko N; Egorova E; Mashkova T
J Matern Fetal Neonatal Med; 2022 Dec; 35(25):6157-6164. PubMed ID: 34044735
[TBL] [Abstract][Full Text] [Related]
2. [Hydroxychloroquine to obtain pregnancy without adverse obstetrical events in primary antiphospholipid syndrome: French phase II multicenter randomized trial, HYDROSAPL].
Mekinian A; Vicaut E; Cohen J; Bornes M; Kayem G; Fain O
Gynecol Obstet Fertil Senol; 2018; 46(7-8):598-604. PubMed ID: 30041771
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment.
Sciascia S; Branch DW; Levy RA; Middeldorp S; Pavord S; Roccatello D; Ruiz-Irastorza G; Tincani A; Khamashta M; Schreiber K; Hunt BJ
Thromb Haemost; 2016 Jan; 115(2):285-90. PubMed ID: 26421409
[TBL] [Abstract][Full Text] [Related]
4. The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome.
Gerde M; Ibarra E; Mac Kenzie R; Fernandez Suarez C; Heer C; Alvarez R; Iglesias M; Balparda J; Beruti E; Rubinstein F
Thromb Res; 2021 Oct; 206():104-110. PubMed ID: 34454240
[TBL] [Abstract][Full Text] [Related]
5. Hydroxychloroquine and antiphospholipid antibody-related pregnancy morbidity: a systematic review and meta-analysis.
Frishman M; Radin M; Schreiber K
Curr Opin Obstet Gynecol; 2020 Oct; 32(5):351-358. PubMed ID: 32675702
[TBL] [Abstract][Full Text] [Related]
6. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Hamulyák EN; Scheres LJ; Marijnen MC; Goddijn M; Middeldorp S
Cochrane Database Syst Rev; 2020 May; 5(5):CD012852. PubMed ID: 32358837
[TBL] [Abstract][Full Text] [Related]
7. Treatment of refractory poor aPL-related obstetric outcomes with TNF-alpha blockers: Maternal-fetal outcomes in a series of 18 cases.
Alijotas-Reig J; Esteve-Valverde E; Llurba E; Gris JM
Semin Arthritis Rheum; 2019 Oct; 49(2):314-318. PubMed ID: 30824278
[TBL] [Abstract][Full Text] [Related]
8. Does adding hydroxychloroquine to empiric treatment improve the live birth rate in refractory obstetrical antiphospholipid syndrome? A systematic review.
Hooper A; Bacal V; Bedaiwy MA
Am J Reprod Immunol; 2023 Sep; 90(3):e13761. PubMed ID: 37641373
[TBL] [Abstract][Full Text] [Related]
9. The effects of hydroxychloroquine and its promising use in refractory obstetric antiphospholipid syndrome.
Fierro JJ; Velásquez-Berrío M; Ospina A; Henning S; de Leeuw K; Cadavid J ÁP
Rheumatol Int; 2024 Feb; 44(2):223-234. PubMed ID: 37741812
[TBL] [Abstract][Full Text] [Related]
10. Triple therapy with pravastatin, low molecular weight heparin and low dose aspirin improves placental haemodynamics and pregnancy outcomes in obstetric antiphospholipid syndrome in mice and women through a nitric oxide-dependent mechanism.
Lefkou E; Varoudi K; Pombo J; Jurisic A; Jurisic Z; Contento G; Girardi G
Biochem Pharmacol; 2020 Dec; 182():114217. PubMed ID: 32926874
[TBL] [Abstract][Full Text] [Related]
11. Anticardiolipin Positivity Is Highly Associated With Intrauterine Growth Restriction in Women With Antiphospholipid Syndrome.
Xi F; Cai Y; Lv M; Jiang Y; Zhou F; Chen Y; Jiang L; Luo Q
Clin Appl Thromb Hemost; 2020; 26():1076029620974455. PubMed ID: 33296221
[TBL] [Abstract][Full Text] [Related]
12. Refractory obstetrical antiphospholipid syndrome: Features, treatment and outcome in a European multicenter retrospective study.
Mekinian A; Alijotas-Reig J; Carrat F; Costedoat-Chalumeau N; Ruffatti A; Lazzaroni MG; Tabacco S; Maina A; Masseau A; Morel N; Esteve-Valverde EE; Ferrer-Oliveras R; Andreoli L; De Carolis S; Josselin-Mahr L; Abisror N; Nicaise-Roland P; Tincani A; Fain O;
Autoimmun Rev; 2017 Jul; 16(7):730-734. PubMed ID: 28478081
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of second-line treatments of refractory and/or high risk pregnant antiphospholipid syndrome patients. A systematic literature review analyzing 313 pregnancies.
Ruffatti A; Tonello M; Favaro M; Del Ross T; Calligaro A; Ruffatti AT; Gervasi MT; Hoxha A
Semin Arthritis Rheum; 2021 Feb; 51(1):28-35. PubMed ID: 33360227
[TBL] [Abstract][Full Text] [Related]
14. Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome.
Bertolaccini ML; Contento G; Lennen R; Sanna G; Blower PJ; Ma MT; Sunassee K; Girardi G
J Autoimmun; 2016 Dec; 75():30-38. PubMed ID: 27160365
[TBL] [Abstract][Full Text] [Related]
15. Upgrading Therapy Strategy Improves Pregnancy Outcome in Antiphospholipid Syndrome: A Cohort Management Study.
Hoxha A; Favaro M; Calligaro A; Del Ross T; Ruffatti AT; Infantolino C; Tonello M; Mattia E; Ruffatti A
Thromb Haemost; 2020 Jan; 120(1):36-43. PubMed ID: 31634958
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis on aspirin combined with low-molecular-weight heparin for improving the live birth rate in patients with antiphospholipid syndrome and its correlation with d-dimer levels.
Shi T; Gu ZD; Diao QZ
Medicine (Baltimore); 2021 Jun; 100(25):e26264. PubMed ID: 34160390
[TBL] [Abstract][Full Text] [Related]
17. Risk Factors for Adverse Maternal and Fetal Outcomes in Women With Confirmed aPL Positivity: Results From a Multicenter Study of 283 Pregnancies.
Fredi M; Andreoli L; Aggogeri E; Bettiga E; Lazzaroni MG; Le Guern V; Lojacono A; Morel N; Piette JC; Zatti S; Costedoat-Chalumeau N; Tincani A
Front Immunol; 2018; 9():864. PubMed ID: 29867924
[TBL] [Abstract][Full Text] [Related]
18. Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated With Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies.
Lazzaroni MG; Fredi M; Andreoli L; Chighizola CB; Del Ross T; Gerosa M; Kuzenko A; Raimondo MG; Lojacono A; Ramazzotto F; Zatti S; Trespidi L; Meroni PL; Pengo V; Ruffatti A; Tincani A
Front Immunol; 2019; 10():1948. PubMed ID: 31475009
[No Abstract] [Full Text] [Related]
19. Intravenous immunoglobulin treatment for obstetric antiphospholipid syndrome refractory to conventional therapy: A single-arm, open-labelled multicentre clinical trial.
Kaneko K; Tsutsumi S; Fujita D; Sugiura-Ogasawara M; Mitsuda N; Matsubara K; Atsumi T; Inoue E; Takimoto T; Murashima A
Mod Rheumatol; 2024 Mar; 34(3):515-522. PubMed ID: 37340865
[TBL] [Abstract][Full Text] [Related]
20. [INDICATIONS FOR ANTITHROMBOTIC MEDICATION DURING PREGNANCY--ANALYSIS OF CURRENT PRACTICES IN BULGARIA].
Neikova K ; Dimitrova V; Dimitrov R; Savov A
Akush Ginekol (Sofiia); 2015; 54(5):3-12. PubMed ID: 26411189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
